Vera Dobelmann (Düsseldorf / DE), Prof. Dr. Yves Allenbach (Paris / FR), Dr. rer. nat. Corinna Preuße (Berlin / DE), Prof. Dr. Matthias Vorgerd (Bochum / DE), Dr. Andreas Hentschel (Dortmund / DE), Dr. med. Anne-Katrin Güttsches (Bochum / DE), Dr. med Felix Kleefeld (Berlin / DE), Dr. med. Christopher Nelke (Düsseldorf / DE), Prof. Dr. med Werner Stenzel (Berlin / DE), Prof., Dr. Olivier Benveniste (Paris / FR), PD Dr. med. Tobias Ruck (Düsseldorf / DE), PD Dr.rer nat Andreas Roos (Bochum / DE; Ottawa, ON / DE; Duisburg-Essen / DE)
Abstract-Text (inkl. Referenzen)
Introduction: Sporadic inclusion body myositis (sIBM) is the most prevalent idiopathic inflammatory myopathy after the age of 50. Pathologically, sIBM is characterized by endomysial infiltrations by terminally differentiated T cells, myodegenerative changes, protein aggregates and fibrosis. As there are currently no established blood biomarkers and a phase III trial for the treatment of sIBM with sirolimus is about to start, we aimed to identify a blood biomarker for sIBM that displays pathophysiological relevance and might hold the potential to indicate therapy response.
Methods: We collected blood samples from sIBM patients (n=56) and non-disease controls (NDC, n=24). Further, biopsy samples from sIBM (n=4) and PM-Mito (Polymyositis with mitochondrial pathology, n=3) patients were included. We performed untargeted proteomics, qPCR, immunohistochemistry studies and ELISA.
Results: We found increased levels of periostin in sIBM muscles by immunohistochemical, proteomic and qPCR results compared to NDC. In contrast, analyses of blood samples from different cohorts of sIBM patients revealed decreased periostin levels (34.57±17.85 ng/mL; p<0.0001) compared to NDC (57.92±23.49 ng/mL).
Discussion: Our study provides preliminary evidence that the fibrosis-modulating protein periostin is a potential blood biomarker for sIBM. Further studies are needed to understand the molecular background and to define the usability in clinical practice.